The AGA Journals Blog highlights the latest discoveries in gastroenterology and hepatology research.

Please note that the AGA Journals Blog is no longer being actively updated. The website will be retired in December 2022. For the latest from our journals, please visit https://www.agajournals.org. Please reach out to [email protected] with any questions.

AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

Patients with inflammatory bowel diseases (IBD) with COVID-19 should delay biological therapies, restarting them once symptoms are gone, says a clinical practice update from the American Gastroenterological Association (AGA).

The practice update, written by David T Rubin et al, says that patients with IBD who test positive for SARS-CoV-2 but have not developed COVID-19 symptoms should hold off on thiopurines, methotrexate, and tofacitinib as well as biological therapies, for 2 weeks while monitoring symptoms. The update is online in the journal Gastroenterology.

The update discusses questions such as:

  • Are Patients with IBD at Increased Risk for Infection with SARS-CoV-2 or Development of COVID-19?
  • Does Inflammation of the Bowel Affect the Course of COVID-19?
  • What Are the Outcomes If a Patient with IBD Develops COVID-19?
  • Do IBD Therapies Affect Risk of Infection with SARS-CoV-2?

Take-home points are:

  • Patients with IBD do not appear to be at increased risk for infection with SARS-CoV-2 or development of COVID-19.
  • Patients with IBD who do not have infection with SARS-CoV-2 should NOT discontinue their IBD therapies and should continue infusion schedules at appropriate infusion centers.
  • Patients with IBD who are infected with SARS-CoV-2 but have not developed COVID-19 should hold off on thiopurines, methotrexate, and tofacitinib. Dosing of biological therapies should be delayed for 2 weeks while monitoring for symptoms of COVID-19.
  • Patients with IBD who develop COVID-19 should hold off on thiopurines, methotrexate, tofacitinib, and biological therapies during their illness. These may be restarted after complete symptom resolution or a negative result from a virus test.
  • The severity of the COVID-19 and the severity of the IBD should be considered in risk to benefit assessment for treatment for of COVID-19 and escalating treatments for IBD.
  • Cases of IBD and confirmed COVID-19 should be submitted to the SECURE-IBD registry at COVIDIBD.org.
Related Posts Plugin for WordPress, Blogger...
Kristine Novak

Kristine Novak

Leave a Replay

About The Author:

Dr. Kristine Novak

Dr. Kristine Novak

Dr. Kristine Novak is a science writer and editor based in San Francisco. She has extensive experience covering gastroenterology, hepatology, immunology, oncology, clinical, and biotechnology research discoveries.

Top Posts:

Subscribe

We never use your email for anything other than The AGA Journals Blog.